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rowth inhibitory proteins in the central nervous sys-
tem (CNS) block axon growth and regeneration by
signaling to Rho, an intracellular GTPase. It is not
known how CNS trauma affects the expression and activation
of RhoA. Here we detect GTP-bound RhoA in spinal cord
homogenates and report that spinal cord injury (SCI) in both
rats and mice activates RhoA over 10-fold in the absence of
changes in RhoA expression. In situ Rho-GTP detection
revealed that both neurons and glial cells showed Rho acti-
vation at SCI lesion sites. Application of a Rho antagonist
(C3–05) reversed Rho activation and reduced the number of
G
 
TUNEL-labeled cells by 
 
 
 
50% in both injured mouse and
rat, showing a role for activated Rho in cell death after CNS
injury. Next, we examined the role of the p75 neurotrophin
receptor (p75
 
NTR
 
) in Rho signaling. After SCI, an up-regulation
 
of p75
 
NTR
 
 was detected by Western blot and observed in
both neurons and glia. Treatment with C3–05 blocked the
increase in p75
 
NTR
 
 expression. Experiments with p75
 
NTR
 
-
null mutant mice showed that immediate Rho activation after
SCI is p75
 
NTR
 
 dependent. Our results indicate that blocking
overactivation of Rho after SCI protects cells from p75
 
NTR
 
-
dependent apoptosis.
 
Introduction
 
Growth inhibitory proteins have long been known to inhibit
axonal regeneration in the central nervous system (CNS)*
(Schwab et al., 1993). These inhibitory proteins are enriched in
myelin, and the three best characterized myelin-derived growth
inhibitory proteins include myelin-associated glycoprotein
(MAG), Nogo, and oligodendrocyte-myelin glycoprotein
(McKerracher and Winton, 2002; Woolf and Bloechlinger,
2002). Recent data indicate that these three inhibitory proteins
bind to the same neuronal receptor, the Nogo-66 receptor
(NgR), but there are additional inhibitory proteins in the
CNS that act through different receptors. More important,
both NgR and NgR-independent inhibitory proteins signal
to activate Rho, a small intracellular GTPase (Niederost et
al., 2002; Winton et al., 2002).
Early experiments demonstrated that lysophosphatidic
acid causes neurite retraction and cell rounding by activating
Rho (Jalink et al., 1994; Tigyi et al., 1996). The use of C3
transferase to inactivate Rho in primary neurons plated on
various types of inhibitory proteins and dominant-negative
Rho-expressing PC-12 cells provides direct evidence that the
inactivation of Rho results in neurite outgrowth on inhibitory
substrates. In vivo experiments in rats and mice have shown
that inactivation of Rho or of Rho kinase promotes axon
regeneration and functional recovery after spinal cord injury
(SCI) in rats and mice (Lehmann et al., 1999; Hara et al.,
2000; Dergham et al., 2002). However, it is not known
how CNS injury may affect Rho expression and activation.
The mechanism where growth inhibitory proteins may affect
Rho signaling are beginning to be understood. It has been
shown recently that NgR can activate Rho in a p75 neurotro-
phin receptor– (p75
 
NTR
 
) dependent manner (Wang et al.,
2002). First, p75
 
NTR
 
-null mutant mice are not inhibited by
MAG, showing a key role of p75
 
NTR
 
 in growth inhibitory
signaling by MAG (Yamashita et al., 2002). Also, Rho binds
to p75
 
NTR
 
 (Yamashita et al., 1999), and Rho is likely to form
part of the membrane raft receptor complex responsible for
growth inhibitory signaling (McKerracher and Winton,
2002; Woolf and Bloechlinger, 2002). Although p75
 
NTR
 
 has
been implicated in apoptosis after SCI (Casha et al., 2001), it is
 
not known to what extent Rho signaling by p75
 
NTR
 
 participates
in apoptotic events after SCI.
Isoforms of Rho exist, and in neurons RhoA is expressed
at higher levels than RhoB and RhoC (Lehmann et al.,
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1999). Therefore, we have focused on RhoA for our studies in
neurons. In nonneuronal cells, Rho family GTPases are best
characterized for their effects on organization and regulation
of the actin cytoskeleton (Ridley, 2001), but they have also
been shown to play a role in the regulation of apoptosis (Jime-
nez et al., 1995; Aznar and Lacal, 2001; Coleman and Olson,
2002). The extent to which Rho may participate in apoptotic
pathways in neuronal cells has yet to be determined. In neu-
rons, Rho is activated in response to chemorepulsive mole-
cules (Jin and Strittmatter, 1997; Wahl et al., 2000) and is
important in axon guidance during development. In adult
neurons, inhibitory substrates (Lehmann et al., 1999; Nied-
erost et al., 2002; Winton et al., 2002) and secreted factors
such as TNF (Neumann et al., 2002) can alter Rho activation
levels. Levels of Rho expression are altered in malignant dis-
ease (Suwa et al., 1998; Fritz et al., 1999; Clark et al., 2000);
however, little is known about how traumatic injury and dis-
ease in the CNS alter Rho activation states in vivo
 
.
 
Rho activation can be studied by probing cell homogenates
with the Rho-binding domain (RBD) from the Rho-GTP–
interacting protein, rhotekin (Reid et al., 1996). We use this
pull-down assay to detect a significant increase in active Rho
in CNS tissue homogenates after SCI. We show that SCI
causes an increase in active Rho without affecting RhoA ex-
pression levels. We made use of an in situ pull-down assay (Li
et al., 2002) to determine that neurons and glia in the spinal
cord show Rho activation. To test the use of a Rho antagonist
to reverse Rho activation, we used a cell-permeable form of
C3 transferase (C3–05) that has a short transport sequence
added to the COOH terminal to help entry into cells (Win-
ton et al., 2002). We show that C3–05 specifically inactivates
Rho in vivo and prevents up-regulation of p75
 
NTR
 
. Treatment
of injured spinal cord with C3–05 not only effectively re-
versed Rho activation but also had cell protective effects.
 
Results
 
Rho is activated by inhibitory substrates
 
To examine the effect of growth-inhibitory proteins on Rho
activation, we plated PC-12 cells on myelin, MAG, or poly-
 
L
 
-lysine substrates. We measured amounts of GTP-Rho in
cell lysates by precipitation with RBD from rhotekin that
binds only GTP-bound Rho (Reid et al., 1996). Cells plated
on inhibitory substrates had high endogenous Rho-GTP lev-
els compared with poly-
 
L
 
-lysine controls (Fig. 1 A). The ac-
tivation of Rho in cells plated on myelin or MAG was re-
versed by treatment with the Rho antagonist C3–05 (Fig. 1
B). The RBD beads incubated without lysate (buffer only)
show no active Rho when overexposed GST-RBD is detect-
able (Fig. 1 C), showing the specificity of the assay for Rho.
Treatment of neuronal cells with C3–05 promotes neurite
outgrowth on MAG or myelin substrates (Winton et al.,
2002). Our results with MAG and myelin are consistent
with recent studies showing Rho activation in the presence
of Nogo (Niederost et al., 2002) or upon activation of Nogo
receptor (Wang et al., 2002).
 
Rho is activated after traumatic SCI
 
To investigate RhoA activation states after traumatic CNS
injury, we measured active RhoA levels in rodent tissue ho-
mogenates by Rho pull-down assay. We studied tissue iso-
lated from regions of traumatically injured spinal cords of
both rats and mice because of their different responses to in-
jury. Rats develop an extensive necrotic lesion cavity after
SCI, whereas mice do not (Steward et al., 1999). In rats, we
examined spinal cord regions after transection or contusion
injury. Experiments are shown as paired control and injured
CNS samples (Figs. 2 and 3). Homogenates from different
animals were not pooled, and each gel lane represents results
from one animal. In uninjured CNS tissue, GTP-Rho levels
were consistently low (Fig. 2, controls). By contrast, Rho ac-
tivation is dramatically increased after injury (Fig. 2, A and
B), increasing over 10-fold (Fig. 2 C). Expression levels of
total RhoA, as detected by Western blots from tissue homo-
genates used for isolation of GTP-Rho, did not change (Fig.
2, A and B). These results show that Rho is massively acti-
vated in CNS tissue of rats and mice after SCI compared
with uninjured spinal cord. To examine if the activation of
Rho after SCI injury was sustained or transient, we prepared
homogenates from transected spinal cord 1.5 h, 24 h, 3 d,
and 7 d after lesion. Interestingly, we found that Rho was
active as early as 1.5 h after injury. The significant increase
in activation observed by 24 h was sustained for at least 7 d
(Fig. 2, B and C).
In neuronal-like cells (PC-12), Rho becomes activated
when cells are plated on substrates of MAG or myelin (Fig. 1
A). It has also been shown that MAG is not only present in
Figure 1. RhoA is activated when cells are plated on growth 
inhibitory substrates. (A) Rho activation levels were examined in 
vitro in PC-12 cells plated on either poly-L-lysine, myelin (8  g), or 
MAG (8  g). Active GTP-bound RhoA was isolated by pull-down 
assay 24 h after the cells were plated on substrates and detected by 
immunoblotting with anti-RhoA antibody. Total Rho levels were 
determined from whole cell lysates as shown in the bottom panel. 
(B) Reversal of Rho activation by treatment of cells with C3–05. 
PC-12 cells plated on myelin were treated with C3–05 (1  g/ml), 
and Rho-GTP levels were detected by pull-down assay. The middle 
panel shows total Rho levels, and the bottom panel shows whole 
cell lysates probed with an anti-C3 antibody. Samples for pull-down 
assays and total Rho and C3 blots were from the same homogenates. 
(C) Pull-down assay with GST-RBD without lysate. Beads incubated 
with buffer only show no active Rho; only GST-RBD band is detected 
when blot is overexposed.T
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myelin but is released from damaged white matter after in-
jury (Tang et al., 2001). To confirm that growth inhibitory
proteins were present in the lesion sites after SCI, we exam-
ined MAG expression levels after injury. The same tissue ho-
mogenates used for the experiments in Fig. 2 B were probed
with a monoclonal antibody raised against MAG. MAG lev-
els remain unchanged; minimal protein degradation was vis-
ible in overexposed blots (Fig. 2 D). The sustained activa-
tion of Rho after SCI may result, in part, from contact of
damaged cells with myelin-derived inhibitory proteins.
 
Treatment with C3–05 reverses Rho activation 
after injury
 
To test if we could reverse the increase in Rho activation in
injured spinal cord, we made use of the Rho antagonist C3–
05 (Winton et al., 2002). We injected C3–05 in a fibrin ma-
trix into the lesion site after spinal cord transection, or C3–
05 alone into contused spinal cord, and the lesion sites were
removed 24 h later. Treatment with C3–05 inactivated Rho,
bringing the RhoA activation levels back to the normal basal
state (Fig. 3, A and B). To determine if the reversal of Rho
activation was sustained after a single injection of the com-
pound, we examined rats 7 d after transection injury and
treatment. Even 7 d after C3–05 treatment, Rho activation
still remained at basal levels (Fig. 3, A and B). Next, we
asked if C3–05 remained at the lesion site after treatment.
Probing the homogenates with a polyclonal antibody raised
against C3 (Winton et al., 2002) demonstrated that C3–05
was detected at the lesion site at all of the time points tested
(Fig. 3 A). To determine if endogenous cells in the spinal
cord were able to take up and retain C3–05 after treatment,
we examined sections of rat spinal cord double labeled with
an antibody specific for C3 and with cell type–specific
markers. We detected intracellular C3 immunoreaction in
neurons, astrocytes, and oligodendrocytes after injection of
C3–05 (Fig. 3 C), showing that endogenous cells from the
spinal cord take up C3–05 in vivo.
 
Rho is active in neurons and glial cells after SCI
 
Although the location of C3–05 can indicate the potential to
suppress Rho activation, it does not permit us to determine
which cells have increased Rho activation after SCI. To fur-
ther examine increased GTP-Rho after SCI, we used a modi-
fied in situ pull-down method, omitting cell transfection
with recombinant Rho (Li et al., 2002) to detect endogenous
Rho activation levels. We incubated sections with GST-
RBD, and cells that bound high levels of RBD were detected
with an anti-GST antibody. Active Rho was detected in
many cells in both the gray (Fig. 4, panels 1 and 2) and white
matter (Fig. 4, panel 3) of injured spinal cord. We also found
that Rho was activated both rostral (Fig. 4, panel 1) and cau-
dal (Fig. 4, panel 2) to the lesion site. At further distances
from the lesion site, staining for active Rho was very faint or
absent (Fig. 4, panel 4). Rho-GTP was not detected in unin-
jured spinal cord (Fig. 5 A, left) or after C3–05 treatment
was used to reverse the increase in Rho activation after SCI
Figure 2. RhoA activation in normal and injured spinal cord tissue. (A) RhoA was examined in normal rat and mouse spinal cord homogenates 
(control) and homogenates prepared 24 h after transection or contusion injury, as indicated (lesion). Active GTP-RhoA was isolated by pull-
down assay and detected by immunoblot with anti-RhoA antibody. Total Rho in the tissue homogenates from the same animals was detected 
by immunoblot with anti-RhoA antibody. (B) RhoA is activated as early as 1.5 h postinjury, and activation was sustained for at least 7 d after 
injury. (C) Quantitative analysis by densitometry of GTP-RhoA after transection of rat spinal cord shown as mean   SEM for all animals 
examined; 24 h (n   5), 3 d (n   3), and 7 d (n   3). n represents the number of animals. *P   0.05 compared with uninjured control; P value 
determined by unpaired t test. (D) Western blot showing MAG at the lesion sites at all time points tested; second panel shows overexposed 
blot to see MAG degradation present after injury (5  g of protein was loaded per lane). Immunoreaction to purified MAG and myelin with the 
MAG antibody are shown in the last panel.T
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(Fig. 5 A, middle). To assess the specificity of the technique,
we incubated sections with GST without RBD, and no posi-
tive cellular active Rho staining is visible (Fig. 5 A, right).
To specifically determine which cell types express active
Rho, sections were double labeled with cell type–specific
markers. We detected active Rho in neurons, astrocytes, and
oligodendrocytes 24 h, 3 d, and 7 d after injury (Fig. 5 B).
Therefore, the activation of Rho observed after injury (Figs.
2 and 3) is an endogenous cellular response (Fig. 5 B). The
ability to detect GTP-Rho without prior transfection (Li et
al., 2002) confirms the high level of endogenous active Rho
in neurons and glia after SCI.
 
Treatment with C3–05 protects cells from apoptosis 
after injury
 
Both neurons and glia undergo apoptosis after SCI in rat,
which leads to the formation of a large lesion cavity (Liu et
al., 1997; Shuman et al., 1997; Grossman et al., 2001). Even
though mice do not develop cavitation at the site of SCI, we
detected apoptotic neurons, astrocytes, and oligodendro-
cytes by double staining with cell-specific markers and
TUNEL (Fig. 6 A, top), similar to that observed after rat
SCI (Fig. 6 A, bottom). Importantly, in both mice and rats
treated with C3–05, the number of TUNEL-labeled cells
was significantly reduced by 
 
 
 
50% after SCI (Fig. 6 B).
Not only was C3–05 present in neurons, astrocytes, and oli-
godendrocytes (Fig. 3 C), but most cells containing C3–05
were not TUNEL positive (Fig. 6, C and D). The small
number of cells double labeled with C3 and TUNEL (16%)
suggests that C3–05 penetrated into some cells that had pro-
gressed too far into the apoptotic cascade to be rescued from
death. Together our results indicate that inactivation of Rho
after SCI protects cells from apoptosis. These findings have
clinical relevance because neuroprotective treatments after
SCI lead to improved functional recovery (Liu et al., 1997).
 
Inhibitory substrates regulate Rho activation after 
injury by a p75-dependent mechanism
 
It has been shown recently that MAG activates Rho in the
presence of p75
 
NTR
 
 (Yamashita et al., 2002) and that MAG
interacts with neuronal lipid rafts containing NgR, GT1b,
p75
 
NTR
 
, and Rho (Vinson et al., 2003). We have shown that
after SCI, MAG is present at the lesion sites (Fig. 2 D). To
determine the mechanism by which Rho is activated after
Figure 3. Treatment with the Rho antagonist 
C3–05 after contusion or transection of the 
spinal cord reverses RhoA activation after 
injury. (A) Injection of C3–05 into the injury 
site reversed RhoA activation to basal levels 
after SCI. Active GTP-RhoA was isolated by 
pull-down assay and detected with antibodies 
specific for RhoA. Total RhoA from the same 
animals was detected by immunoblot. Anti-C3 
antibody immunoblot of the same homogenate 
showed C3–05 was detected at the lesion site 
for 7 d (C3–05). The same homogenates were 
used to determine levels of Rho and C3. 
(B) Densitometric analysis of the reversal of Rho 
activation by C3–05 after mouse hemisection 
(n   2); rat contusion (n   3); rat transection 
after 24 h (n   3); rat transection after 3 d 
(n   3); and rat transection after 7 d (n   2). 
n represents the number of animals. *P   0.05 
compared with lesion without treatment; 
P value determined by unpaired t test. (C) Double 
immunocytochemistry with cell-type specific 
markers (red) and a specific antibody against 
C3 (green). Neurons (NeuN), astrocytes (GFAP), 
and oligodendrocytes (MAB328) show C3 
immunoreactivity within cells in injured rat 
spinal cord treated with C3–05. Bars, 50  m.T
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injury, we examined if Rho activation was p75
 
NTR
 
 depen-
dent. We first examined if p75
 
NTR
 
 was present in cells con-
taining active Rho. We found that p75
 
NTR
 
 colocalizes with
active Rho in both gray (Fig. 7 A, top) and white matter
(Fig. 7 A, bottom) 24 h after SCI. We then examined levels
of active Rho in mice lacking the p75
 
NTR
 
 gene (p75
 
NTR
 
 
 
/
 
 
 
).
No change in Rho activation was detected 24 h after SCI
(Fig. 7 B). Rho activation was, however, detected in these
animals 3 d after injury (Fig. 7 C). These results indicate
that Rho is activated through a p75
 
NTR
 
-dependent mecha-
nism early after SCI, but at later time points p75
 
NTR
 
-inde-
pendent activation occurs.
The p75
 
NTR
 
 has been implicated in the regulation of
apoptosis after injury in the nervous system (Cheema et al.,
1996; Frade and Barde, 1999; Dechant and Barde, 2002).
In addition to counting TUNEL cells after SCI (Fig. 6 B),
we counted p75
 
NTR
 
-labeled cells and double labeled cells.
Many cells express p75
 
NTR
 
 after SCI (Fig. 8 B), and 74% of
these cells were also TUNEL positive. Treatment with C3–
05 resulted in a decrease in p75
 
NTR
 
 alone and in p75
 
NTR
 
and TUNEL (Fig. 8, A and B). These results suggest a cor-
relation between Rho activation, p75
 
NTR
 
 expression, and
cell death. To further investigate the involvement of
p75
 
NTR
 
 in Rho activation after SCI, we probed the homog-
enates of transected spinal cord with p75
 
NTR
 
-specific anti-
bodies using the same homogenates as shown in the bot-
tom panel of Fig. 8 C. There was very low p75
 
NTR
 
 detected
in Western blots in the adult spinal cord (Fig. 7 B and Fig.
8 C, controls). Levels of p75
 
NTR
 
 increased as early as 24 h
after SCI, and high levels were detected 3 and 7 d postin-
jury, a finding consistent with previous reports of p75
 
NTR
 
up-regulation after SCI (Casha et al., 2001; Widenfalk et
al., 2001; Beattie et al., 2002). Treatment with C3–05 not
only blocked the increase in p75
 
NTR
 
 protein levels after
SCI, as detected by Western blot (Fig. 8 C), but also re-
duced the number of p75
 
NTR
 
-TUNEL–labeled cells (Fig. 8
B). These results suggest, that early on, Rho activation after
SCI is mediated, at least in part, by p75
 
NTR
 
. These results
also indicate that Rho activation is important for p75
 
NTR
 
up-regulation after SCI.
 
Discussion
 
It is now well established that neurons in the CNS respond
to negative growth inhibitory cues and positive growth-
promoting signals. Much work has underlined the impor-
Figure 4. Rho is activated in a large population 
of cells rostral and caudal to the lesion site. 
(Top) Nissel-stained longitudinal section of rat 
spinal cord 24 h after dorsal over-hemisection. 
Bar, 1 mm. Higher magnification of areas 
spanning the section are shown boxed and 
numbered. Magnified panels 1–4 show active 
Rho (GST-RBD detection) in a large number of 
cells spanning the lesion site. Panel 1 shows 
active Rho in gray matter rostral to the lesion, 
panel 2 shows active Rho in gray matter caudal 
to the lesion, panel 3 shows active Rho in white 
matter ventral to the lesion, and panel 4 shows 
an absence of GST-RBD detection distal to the 
lesion. Bars, 100  m.T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
C
e
l
l
 
B
i
o
l
o
g
y
 
238 The Journal of Cell Biology 
 
|
 
 
 
Volume 162, Number 2, 2003
 
tance of myelin-derived growth inhibitory proteins ex-
pressed by oligodendrocytes and present in white matter
(Schwab et al., 1993; Schwab, 2002). The consequence of a
growth inhibitory environment in the CNS is that injured
neurons fail to regrow their transected axons even though
they have an inherent capacity to regenerate. The molecu-
lar mechanisms of neuronal growth after injury have been
widely studied in order to promote regeneration after SCI
(David and Lacroix, 2003). Work from our lab and others
has established that inactivation of Rho signaling is suffi-
cient to promote axon growth on growth inhibitory sub-
strates (Jin and Strittmatter, 1997; Lehmann et al., 1999;
Dergham et al., 2002; Niederost et al., 2002; Fournier et
al., 2003) and to stimulate axon regeneration after SCI
(Hara et al., 2000;
 
 
 
Dergham et al., 2002; Fournier et al.,
2003). We have shown here that Rho is activated when
neuronal like cells are plated on myelin and that Rho is sig-
nificantly activated in neurons and glia in vivo after SCI.
We report that administration of C3–05 reverses Rho inac-
tivation in vivo and protects cells from apoptotic cell death.
We further show a role for p75
 
NTR
 
 in mediating Rho acti-
vation after SCI.
 
Mechanisms for sustained Rho activation after SCI
 
Activation of Rho in CNS tissue after SCI injury likely re-
sults from changes in the local inhibitory and inflammatory
environment. Both neurons and glial cells show increased
Rho activation. There is evidence that the inhibitory envi-
ronment of the CNS contributes to increased Rho activation
after SCI. First, we showed that neuronal Rho is activated by
MAG and myelin when PC-12 cells are plated on inhibitory
substrates (Fig. 1). Soluble Nogo fusion proteins can also ac-
tivate neuronal Rho (Niederost et al., 2002; Fournier et al.,
2003). Other evidence indicates that Rho is activated by
NgR-independent growth inhibitory proteins. Inactivation
of Rho promotes neurite growth on chondroitin sulfate pro-
teoglycans (Dergham et al., 2002) that are present at glial
scars. Also, collapsin and ephrins, chemoreplusive factors
that act through different receptors, respectively, both acti-
vate Rho (Jin and Strittmatter, 1997; Wahl et al., 2000).
Preliminary evidence from our lab indicates that astrocytes
plated on inhibitory substrates show Rho activation (unpub-
lished data). Therefore, inhibitory proteins may activate Rho
in both neurons and glial cells by NgR and NgR-indepen-
dent mechanisms.
The inflammatory environment may contribute to Rho
activation after SCI. Reactive astrocytes secrete TNF, and
TNF has been shown to activate Rho in neurons expressing
TNF receptors (Neumann et al., 2002). Inflammation after
injury is considered to cause secondary damage because it
progresses with time and causes continued cell death after
the primary traumatic insult (Schwartz and Fehlings, 2002;
Popovich and Jones, 2003). Our failure to detect Rho acti-
vation in p75
 
NTR
 
-null mutant mice early after SCI (24 h)
suggests activation of NgR signaling to p75
 
NTR
 
 is an early
event in CNS injury. However, 3 d after injury in these mice
Rho activation was observed, a finding that indicates that at
later time points Rho activation is p75
 
NTR
 
 independent.
Many factors activate Rho independently of p75
 
NTR
 
 such as
semaphorins, ephrins, and thrombin that are known to be
present after SCI (Donovan et al., 1997; Wahl et al., 2000;
De Winter et al., 2002; Shirvan et al., 2002; Swiercz et al.,
2002). The p75
 
NTR
 
 dependence of early Rho activation is in-
teresting because thrombin and TNF, both known to acti-
vate Rho, are p75
 
NTR
 
 independent and are present early after
SCI (Donovan et al., 1997; Citron et al., 2000; Lee et al.,
Figure 5. Rho is active in neurons and glial 
cells after SCI, detected by in situ pull-down 
assay. (A) Control uninjured animals (control   
GST-RBD) and C3–05 treatment of animals after 
SCI (C3–05   GST-RBD) probed with GST-RBD 
show no active Rho. Sections of animals after 
SCI incubated with lysate from empty pGEX 
vector expressing only GST protein (lesion   
GST-pGEX) show only background levels of 
GST in the spinal cord and no active Rho. 
Bar, 50  m. (B) Double labeling of spinal cord 
with cell type–specific markers (red) and GST 
antibody to detect GST-RBD (green). At all time 
points tested (24 h, 3 d and 7d), GTP-Rho was 
detected in neurons (NeuN), astrocytes (GFAP), 
and oligodendrocytes (MAB328) after SCI. 
Bars, 50  m.T
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2000). Our experiments with the p75
 
NTR
 
 knockout mice
were with whole tissue homogenates and do not address sig-
nificant changes in individual cell types early after injury.
The massive Rho activation we observe in normal mice and
rats after SCI likely represents the combined effects of the
many different Rho-activating factors. Secondary damage by
inflammation may also contribute to activation of Rho, and
if this is the case, then Rho may be an important target to
prevent secondary inflammatory damage. Our results after
treatment with C3–05 show that inactivation of Rho re-
duces cell death that follows injury. Further, the massive ac-
tivation of Rho that we observed after injury was sustained
for at least 7 d. Therefore, multiple local signals may activate
Rho in CNS cells. We speculate that continued presence of
growth inhibitory molecules at the site of a CNS lesion con-
tributes to sustained activation of Rho in neurons and glia
after SCI.
 
Rho activation leads to apoptosis after SCI
 
Rho-GTPases are known regulators of apoptosis in various
cell types. In nonneuronal cells, such as epithelial cells
(Fiorentini et al., 1998a,b), endothelial cells (Hippenstiel et
al., 2002), T cells (Moorman et al., 1996; Gomez et al.,
1997), and some fibroblasts (Bobak et al., 1997), inactiva-
tion of Rho causes apoptosis through a Bcl-2–dependent
mechanism. In other cells, such as PC-12 cells (Mills et al.,
Figure 6. Inhibition of Rho activation with 
C3–05 protects cells from apoptosis. (A) Sections 
of injured spinal cords from mouse (top) and rat 
(bottom) were double labeled with specific cell 
markers NeuN, GFAP, or MAB328 (red) and 
by TUNEL (green) to detect apoptotic cells. 
Bar, 50  m. (B) Treatment of injured spinal 
cord with C3–05 significantly decreased the 
number of TUNEL-positive cells counted in 
both mice (right) and rats (left). TUNEL-positive 
cells were counted in 40–50 sections per animal 
taken from a 3- or 4-mm segment of the lesion 
site in mice and rats, respectively, with three 
animals examined per group. *P   0.05 
compared with lesion without treatment; P value 
determined by unpaired t test. (C) Sections 
from rat spinal cord showing that most C3 
immunostained cells were not TUNEL positive. 
Bar, 50  m. (D) C3-labeled cells are less likely 
to be TUNEL positive. C3 and TUNEL cells 
were counted and compared with the number 
of TUNEL-labeled cells in C3–05–treated 
animals.T
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1998) and endogenous cells of the spinal cord, as we show
here, inactivation of Rho protects cells from apoptosis. In
NIH 3T3 fibroblasts, overexpression of active Rho induces
cell death upon serum withdrawal (Jimenez et al., 1995).
Thus, the cell background is critical in the effect of Rho sig-
naling and cell death. In PC-12 cells, a neural cell line, Rho
proteins have been shown to induce Rho-dependent mem-
brane blebbing (Mills et al., 1998), a morphological charac-
teristic of apoptosis. In cultured astrocytes and hippocampal
neurons, treatment with thrombin, a protease found after
CNS trauma, causes Rho-dependent apoptosis. Treatment
with C3 reversed the thrombin-induced apoptosis of astro-
cytes and neurons by  50% (Donovan et al., 1997). In neu-
rons, TNF activates Rho (Neumann et al., 2002), and anti-
body-mediated blocking of TNF reduces apoptosis after SCI
(Lee et al., 2000). These data support our direct evidence
that Rho activation contributes to apoptosis after traumatic
SCI. Rho activation in neurons alone may not be sufficient
to cause cell death, such as when neurons are plated on in-
hibitory substrates in culture. Our data suggest that in vivo
the combination of multiple Rho-activating factors, includ-
ing the myelin-derived inhibitory factors, contribute to ap-
optotic signaling cascades.
Mechanism of Rho activation
Our results show that blocking the activation of Rho after
SCI prevents an increased synthesis of p75
NTR protein (Fig.
8 C), implicating Rho activation in the transcriptional
changes in p75
NTR expression. This result of C3–05 can be
explained by a mechanism in which the change in transcrip-
tional factor activation is Rho dependent (Fig. 9). It is
known that Rho is involved in the activation of transcription
factors in the nucleus that control synthesis of proapoptotic
Figure 7. Rho is activated after SCI by a p75
NTR-dependent 
mechanism. (A) p75
NTR-labeled cells colocalize with active GTP-Rho 
in injured spinal cord. Cells labeled with p75
NTR (red) and GST-RBD 
(green) in gray matter (top) and in white matter (bottom). Bars, 100  M. 
(B) Rho activation after SCI in normal and p75
NTR /  mice. 
Active GTP-RhoA was isolated by pull-down assay and detected by 
immunoblotting with anti-RhoA antibody (top). In p75
NTR /  mice, 
24 h after injury only basal levels of active Rho are detected compared 
with normal mice. Paired samples were run on the same gel, and 
blots were developed under the same conditions. Total Rho in 
the tissue homogenates from the same animals was detected by 
immunoblotting with anti-RhoA antibody. MAG was detected in the 
same homogenates by Western blot (apparent MW 100 kD). The 
p75
NTR levels (apparent MW 75 kD) are shown in bottom panel. In 
control uninjured animals low levels of p75
NTR are detected, with 
p75
NTR only being up-regulated after injury. (C) Active Rho is detected 
in p75
NTR /  mice 3 d after SCI.
Figure 8. Rho regulates p75
NTR expression after injury. (A) Transverse 
sections throughout rat lesion sites show cells double labeled 
with p75
NTR-specific antibody (red) and with TUNEL (green). 
Bar, 50  m. (B) The number of p75
NTR-labeled cells (left) and p75
NTR 
cells positive for TUNEL (right) in transverse sections of rat spinal 
cord after injury. (C) The p75
NTR protein levels increase after SCI 
but not after treatment with C3–05. Detection of p75
NTR by 
Western blot after SCI and treatment with C3–05. The same tissue 
homogenates used to show active Rho, shown in bottom panel, 
were probed with a p75
NTR-specific polyclonal antibody (top) and 
an anti-C3 antibody (panel 2). RhoA in whole tissue homogenate 
from the same animals is also shown (panel 3). Last panel shows 
GTP-bound active Rho.T
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mRNAs such as c-jun and NF  , members of the p75
NTR
apoptotic cascades (Aznar and Lacal, 2001; Huang and
Reichardt, 2001). Therefore, we speculate that treatment
with C3–05 to block Rho activation after injury suppresses
apoptosis by preventing the synthesis of proapoptotic pro-
teins such as p75
NTR.
The p75
NTR contributes to initial apoptotic cascades that
follow injury in the CNS. In oligodendrocytes, an increase
in the expression of p75
NTR after SCI leads to apoptotic cell
death (Casha et al., 2001; Beattie et al., 2002). In astrocytes,
p75
NTR expression is observed after exposure to inflamma-
tory cytokines (Hutton et al., 1992; Semkova and Kriegl-
stein, 1999), also known to activate Rho (Neumann et al.,
2002). In neurons, apoptosis after growth factor deprivation
is mediated by p75
NTR (Kaplan and Miller, 2000), and re-
ducing p75
NTR levels prevents death of axotomized neurons
(Cheema et al., 1996). Reducing p75
NTR levels reduces
apoptosis in contused spinal cord (Brandoli et al., 2001). In
p75
NTR /  mice there is a decrease in apoptosis in the spi-
nal cord (Frade and Barde, 1999). We have shown that both
neurons and glia have unusually high levels of active Rho af-
ter SCI (Fig. 5 B). Moreover, reversal of Rho with C3–05
reduced apoptosis (Fig. 6 B) and prevented p75
NTR up-regu-
lation (Fig. 8, B and C). Together these results indicate that
Rho activation induces apoptosis in a p75
NTR-dependent
manner early on after SCI and that inactivation of Rho is
cell protective.
Materials and methods
Surgical procedures
Rats were anaesthetized under 2–3% isoflurane. For SCI, adult female
Long-Evans rats (200–250 g) underwent laminectomy at thoracic level
T10-T11 for SCI at T10. Control animals were sham operations with lami-
nectomy only. Dorsal over-hemisections were done at a depth of 1.6 mm.
For contusion experiments, the NYU impactor device was used with 10 g
at 25 mm. From 24 h to 7 d after SCI, animals received an overdose of
chloral hydrate anaesthetic, were perfused with saline, and the spinal
cords were removed. Approximately 5 mm surrounding the injured area
was isolated and frozen at –80 C. Balb/c female mice (20–22 g) and p75
knockout mice (Lee et al., 1992) (Jackson mice, stock number 002213)
were anaesthetized with hypnorm (20 ml/Kg) and diazepam (1 mg/Kg).
Dorsal over-hemisections were performed at T8: n   5 at 24 h and n   5
at 3 d. After perfusion with saline, 2–3 mm of spinal cord from the lesion
site was removed for analysis. After SCI, bladders of all animals were ex-
pressed two to three times per day. Rats were given 5 ml of 0.9% saline
subcutaneously twice a day for 1 wk and received daily subcutaneous in-
jections of baytril (10 mg/Kg).
To treat rats with a Rho antagonist, 50  g of C3–05 was injected in a fi-
brin matrix (Tisseel kit; Baxter) into transected spinal cord as described
(Dergham et al., 2002). In mice, 10  g of C3–05 in fibrin was injected, ex-
cept for the experiment for TUNEL labeling where 1  g in fibrin was in-
jected. C3–05 (50  g) in PBS without fibrin was injected into rat contusion
injury sites. All animal procedures followed guidelines from the Canadian
Council of Animal Care.
Cell culture
PC-12 cells were grown in DME with 10% horse serum, 5% FBS, 1% pen-
icillin-streptomycin. PC-12 cells were grown on poly-L-lysine (0.1  g/ml)
(Sigma-Aldrich) or myelin (8  g per well) or MAG- (8  g) coated 6-well
culture dishes. After the cells settled (3–6 h at 37 C), the media was aspi-
rated, and fresh media containing the C3–05 (1  g/ml) was added to the
undifferentiated cultures. The cells were harvested 24 h later, washed with
ice cold TBS, and lysed in modified RIPA buffer (50 mM Tris, pH 7.2, 1%
Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, 500 mM NaCl, 10
mM MgCl2, 10  g/ml leupeptin, 10  g/ml aprotinin, 1 mM PMSF). Cell ly-
sates were clarified by centrifugation at 13,000 g for 10 min at 4 C and
kept at  80 C.
Pull-down assays and immunoblotting
Purification of GST-RBD was performed as described previously (Ren and
Schwartz, 2000). Bacteria expressing GST-RBD in a pGEX vector (a gift
from John Collard, Division of Cell Biology, Netherlands Cancer Institute,
Amsterdam, Netherlands) were grown in L-broth with 100  l/ml ampicil-
lin. Overnight cultures were diluted 1:10 into 3,600 ml L-broth and incu-
bated in a shaking bacterial incubator at 37 C for 2 h. Isopropyl- -D-
thiogalactopyranoside (0.5 mM) was then added to the incubating cultures
for 2 h. Bacteria were collected by centrifugation at 5,000 g for 15 min.
The pellets were resuspended in 40 ml lysis buffer (50 mM Tris, pH 7.5,
1% Triton X, 150 mM NaCl, 5 mM MgCl2, 1 mM DTT, 10  g/ml leupep-
tin, 10  g/ml aprotinin, 1 mM PMSF). After sonication, the lysates were
spun at 14,000 rpm for 30 min at 4 C. The clarified bacterial lysate was
then incubated with glutathione agarose beads (0.6 ml wet volume; pre-
swelled with water) (Sigma-Aldrich) for 60 min at 4 C. The coupled beads
were then washed six times in wash buffer (50 mM Tris, pH 7.5, 0.5% Tri-
ton X-100, 150 mM NaCl, 5 mM MgCl2, 1 mM DTT, 1  g /ml aprotinin, 1
 g/ml leupeptin, and 0.1 mM PMSF) and once in wash buffer containing
10% glycerol. Beads were then resuspended in 8 ml of the wash buffer
containing 10% glycerol and stored overnight at  80 C. Frozen tissue was
homogenized in modified RIPA buffer (50 mM Tris, pH 7.2, 1% Triton
X-100, 0.5% sodium deoxycholate, 0.1% SDS, 500 mM NaCl, 10 mM
MgCl2, 10  g/ml leupeptin, 10  g/ml aprotinin, 1 mM PMSF). The ho-
mogenates and cell lysates were clarified by two 10-min centrifugations at
13,000 g at 4 C. They were then incubated for 50 min at 4 C with GST-
RBD (a gift from John Collard, Division of Cell Biology, Netherlands Can-
cer Institute, Amsterdam, Netherlands) coupled beads (20–30  g/sample).
The beads were then washed four times and eluted in sample buffer. GTP-
bound Rho and total Rho present in tissue homogenates were detected by
Western blot. The proteins were transferred to nitrocellulose and probed
using a monoclonal RhoA antibody (Santa Cruz Biotechnology, Inc.).
Bands were visualized with peroxidase-linked secondary antibodies
(Promega) and an HRP-based chemiluminescence reaction (Pierce Chemi-
cal Co.). C3–05 was detected using a C3-specific polyclonal antibody
(Winton et al., 2002). P75
NTR was detected with a polyclonal antibody
Figure 9. Schematic diagram showing possible apoptotic cascade 
mediated by Rho after SCI. Both myelin-derived growth inhibitory 
proteins (Fig. 1) and TNF (Neumann et al., 2002) directly activate 
Rho. P75
NTR activates Rho in the absence of neurotrophin binding 
(Yamashita et al., 1999). The inactivation of Rho by C3–05 after 
SCI blocks the increase of p75
NTR protein levels (Fig. 8 C) and 
inhibits apoptosis (Fig. 6, B and C). Inactivation of Rho with C3–05 
both prevents apoptosis, as shown in this paper, and stimulates 
regeneration (Lehmann et al., 1999; Dergham et al., 2002). Gray 
lines indicate C3–05 treatment and inactivation of Rho; black lines 
indicate the effects of active GTP-bound Rho.T
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raised against p75
NTR (Promega). For all blots, 20  g of protein was loaded
into each lane. Blots were scanned for densitometry using an Epson perfec-
tion 1200U scanner, transferred to Adobe Photoshop
® 6.0, and the images
were the analyzed with the densitometry IQ MAC 1.2 software (Molecular
Dynamics). The software measures the pixel density in the band image af-
ter background subtraction, and the densitometry value is in arbitrary
units. Statistical tests were performed using In Stat (Graph Pad).
For in situ pull-down assays, rat spinal cord cryosections (16- m thick-
ness, fresh) were postfixed with 4% PFA and incubated with the clarified
bacterial lysate, prepared from bacteria expressing GST-RBD or GST
alone, as described above, overnight at 4 C. The sections were then
washed three times in TBS, blocked in 3% BSA for 1 h at room tempera-
ture, and incubated with anti-GST antibody (New England Biolabs, Inc.)
and with cell type–specific antibodies (NeuN, GFAP, and MAB328;
Chemicon) or with antibody raised against p75
NTR (Promega) overnight at
4 C. Sections were washed in TBS and incubated for 2 h at room tempera-
ture with FITC, Texas red, or rhodamine-conjugated secondary antibodies
(Jackson ImmunoResearch Laboratories).
TUNEL labeling and immunohistochemistry
Spinal cord samples of 3 and 4 mm spanning the lesion sites of mice and
rats, respectively, were dissected. Normal spinal cord was a 4-mm section
from sham control cords. All spinal cord pieces were postfixed in 4% PFA,
washed, and embedded in paraffin. Transverse sections of 6- m thickness
were cut, deparaffinized in xylene, and rehydrated by ethanol washes.
TUNEL labeling was performed using the Fluorescein-FragEL DNA Frag-
mentation kit (Oncogene Research Products). The sections were costained
with Hoechst 33342 (Sigma-Aldrich), and only TUNEL-positive cells that
correlated with Hoechst 33342–stained nuclei were counted. To quantita-
tively examine the numbers of apoptotic cells, TUNEL-positive cells were
counted on sections from control, lesion, and C3–05–treated animals. A
blinded researcher counted the total number of TUNEL-positive cells lo-
cated in the entire transverse section. The average number of TUNEL-posi-
tive cells per section was calculated from values obtained by counting 40–
50 random sections throughout the lesion site of each animal, with three
animals examined per group. The TUNEL-positive cells (green) were distin-
guished from autofluorescent macrophages (red) through the use of a merge
red/green filter. Cells labeled with both TUNEL (green) and p75 (red) were
counted in a merge red/green filter after verifying colocalization with
Hoechst stain. Values were obtained by counting 20 random sections
throughout the lesion site of each animal, with three animals examined per
group. Immunohistochemistry with cell type–specific antibodies (NeuN,
GFAP, and MAB328; Chemicon) or with a polyclonal C3 antibody (Winton
et al., 2002) was performed on paraffin sections. After deparaffinization,
transverse sections were treated with 2  saline sodium citrate at 80 C for
20 min. Sections were blocked in TBS containing 3% BSA and 2% goat se-
rum and incubated overnight with primary antibody at 4 C followed by a
2-h incubation with FITC or Texas red–conjugated secondary antibodies
(Jackson ImmunoResearch Laboratories). All pictures were taken with
northern eclipse software and transferred to Adobe Illustrator
® 9.0.
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